Association of serum MMP-9,CYRFA21-1,and VEGF levels on cisplatin treatment efficacy in patients with non-small cell lung cancer
WANG Haiying
WU Kai
TIAN Yinchun
Abstract：Objective To investigate the relationship between serum matrix metalloproteinase-9(MMP-9),cytokeratin 19 fragment(CYRFA21-1)and vascular endothelial growth factor(VEGF)levels and cisplatin treatment in patients with non-small cell lung cancer.Methods 130 advanced B-stage non-small cell lung cancer treated with cisplatin in Affiliated Hospital of Nantong University from December 2020 to December 2022 were selected as the study subjects;100 patients with physical examination in our hospital were selected as the control group.By comparing the serum levels of MMP-9,CYRFA21-1 and VE GF in each group,the cisplatin treatment effect was divided into 15 patients and 37 patients in the treatment-effective group,and 78 patients in the treatment-effective group to clarify the relationship between the treatment effect of patients with non-small-cell lung cancer.Results Serum levels of MMP-9,CYRFA21-1 and VEGF were decreased in NSCLC patients after cisplatin treatment(P＜0.05).Compared with the ineffective group,serum MMP-9,CYRFA21-1 and VEGF levels in the significantly effective group and the effective group were decreased(P＜0.05).Logistic regression analysis showed that MMP-9,CYRFA21-1 and VEGF were also risk factors affecting cisplatin treatment effect in NSCLC patients(P＜0.05).ROC analysis showed that serum MMP-9,CYRFA21-1 and VEGF had high predictive value for cisplatin treatment in NSCLC patients(P＜0.05).Conclusions MMP-9,CYRFA21-1 and VEGF are highly expressed in the serum of patients with severe pneumonia,and the expression levels of MMP-9,CYRFA21-1 and VEGF are decreased after cisplatin treatment in patients with non-small cell lung cancer,which is related to the cisplatin treatment effect in patients with non-small cell lung cancer.Clinical monitoring of serum levels of MMP-9,CYRFA21-1 and VEGF can predict the therapeutic effect early to improve the prognosis of patients.
Keywords：non-small cell lung cancercisplatinmatrix metalloproteinase-9cytokeratin 19 frag-mentvascular endothelial cell growth factor
Publication Date：2024-12-25
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：6( 3452-3457 )